NCT06979674View on ClinicalTrials.gov

Study of ESG406 in Adults With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

556

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

June 30, 2028

Conditions
Locally Advanced/Metastatic Solid Tumors
Interventions
DRUG

ESG406

Administered via intravenous (IV) infusion.

Trial Locations (3)

310009

RECRUITING

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

400030

RECRUITING

Chongqing University Cancer Hospital, Chongqing

710061

RECRUITING

The First Affiliated Hospital of Xi 'An Jiaotong University, Xi’an

All Listed Sponsors
lead

Shanghai Escugen Biotechnology Co., Ltd

INDUSTRY